Introduction {#s1}
============

Bisphenol A (BPA), a synthetic chemical used in the manufacture of polycarbonate plastics and epoxy resins, can be found in a variety of consumer products, including some food and beverage cans, plastic bottles, receipts, and medical equipment ([@c33]; [@c39]). BPA is an endocrine-disrupting chemical that acts as a physiological receptor in a variety of pathways ([@c37]). Fetuses are directly exposed to BPA because it crosses the placenta ([@c2]; [@c32]). Several human studies have linked higher levels of BPA exposure during pregnancy to reduced size at birth, as well as to increased risk of adverse birth outcomes ([@c10]; [@c18]; [@c29]; [@c45]), whereas other studies did not report such associations ([@c11]; [@c14]; [@c22]; [@c34]; [@c44]).

In consideration of the toxicity of BPA and consumer concern, manufacturers have begun to remove BPA from their products, with gradual transitions to using bisphenol analogs. As a result, bisphenol F (BPF) and bisphenol S (BPS) have been widely used in manufacturing a variety of BPA-free products ([@c5]; [@c39]). In recent studies, BPF and BPS were detected in some personal care products, receipt paper, and food in several countries, including the United States, China, Japan, and Korea ([@c26]; [@c23], [@c24]). Furthermore, BPF and BPS have also been found in urine samples of populations from the United States, China, and several other countries from Asia and Europe at levels comparable to those of BPA ([@c1]; [@c25]; [@c27]; [@c50]; [@c52]).

Prenatal exposure to BPA may affect fetal growth through multiple hormone-mediated mechanisms because of its properties of mimicking estrogen, inhibiting androgen production, altering thyroid signaling, and causing oxidative stress ([@c32]; [@c46]). In addition, exposure to BPA at levels consistent with plasma concentrations in pregnant women may affect placental functions by inducing the apoptosis of primary human cytotrophoblast cells through tumor necrosis $\text{factor-}\alpha$ ([@c4]). A systematic review of *in vitro* and experimental studies concluded that BPF and BPS might have endocrine-disrupting effects similar to BPA ([@c39]). BPF and BPS have also been shown to affect zebrafish in a manner similar to the effects of BPA at low (environmentally relevant) exposure levels ([@c20]; [@c35]). However, evidence from epidemiological studies is scarce. To our knowledge, only two recent studies have investigated prenatal exposure to BPS in association with birth outcomes, with one reporting an inverse association between detectable (vs. nondetected) maternal urinary BPS concentrations and birth weight ([@c15]) and the other reporting a significant overall association with longer pregnancy duration but not with birth weight or length ([@c48]). To our knowledge, no epidemiological studies have investigated the effect of prenatal exposure to BPF on fetal growth.

In this longitudinal prenatal cohort study in Wuhan, China, we estimated trimester-specific associations of urinary concentrations of BPA, BPF, and BPS with birth weight, birth length, and ponderal index in 845 pregnant women who provided urine samples at three time points during pregnancy. We further investigated whether associations differed by trimester, which would be indicative of windows of heightened susceptibility to bisphenol exposures during pregnancy.

Methods {#s2}
=======

Study Participants {#s2.1}
------------------

The present study was carried out based on an ongoing longitudinal prenatal cohort study in Wuhan, Hubei Province, China. Participants were recruited at Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), the municipal health center for women and children in Wuhan ([@c49]). Pregnant women who received their first prenatal care visits before 16 weeks of gestation were eligible. Women were enrolled in the prenatal cohort study if they *a*) were residents of Wuhan; *b*) comprehended the Chinese language; *c*) agreed to have in-person interviews, take ultrasound examinations, and provide blood and urine samples at different governmental recommended prenatal care visits; *d*) were willing to give birth at the study hospital; and *e*) provided signed informed consent. The present study included 856 women, sampled between October 2013 and October 2015, who satisfied the inclusion criteria, gave birth to live singletons without birth defects, and provided three urine samples, one in each of the three trimesters. Of these, 845 women were retained after additionally excluding women who used tobacco ($n = 5$) or consumed alcohol ($n = 4$) before or during pregnancy, as well as women with missing values in covariates ($n = 2$). The study protocol was reviewed and approved by the ethics committees of Tongji Medical College, Huazhong University of Science and Technology, and of the Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital).

Urine Collection and Analysis {#s2.2}
-----------------------------

Urine samples of pregnant women were obtained at governmental recommended prenatal care visits in the first \[$\text{mean} \pm \text{standard\  \ deviation\  }\left( \text{SD} \right) =$ $13.0 \pm 1.1$ weeks, the first prenatal care visit; range: 10--16 weeks\], second ($\text{mean} \pm \text{SD\  } =$ $23.6 \pm 3.2$ weeks; range: 19--27 weeks), and third ($\text{mean} \pm \text{SD\  } =$ $36.0 \pm 3.4$ weeks; range: 32--41 weeks) trimesters and were stored at $- 20{^\circ}C$ in polypropylene cups prior to analyses. All women included in the present study provided one urine sample in each trimester. Moreover, 688 (81.4%) of the women provided their first-trimester urine samples at or prior to 13 weeks of gestation.

The methods for determining urinary bisphenol concentrations have been described elsewhere ([@c53]). Briefly, a $1\text{-}{mL}$ urine sample was withdrawn from samples after being thawed at room temperature (about 25°C). After adding internal standards of bisphenols, working solutions were incubated overnight for digestion and were then extracted. Before analyzing, the upper organic layers were collected and evaporated under nitrogen gas flow and then reconstituted. Finally, urinary concentrations of BPA, BPF, and BPS were simultaneously measured by an ultra-high performance liquid chromatograph (Dionex) coupled with a triple quadrupole mass spectrometer (Thermo Scientific). Each analytical batch contained all three urine samples of one woman collected at different time periods, as well as blanks and quality control samples. The limits of detection (LODs) were $0.04\text{ \ ng}/{mL}$ for BPA, $0.02\text{ \ ng}/{mL}$ for BPF, and $0.04\text{ \ ng}/{mL}$ for BPS. The linear ranges of the calibration curves ranged from 1.00 to $50\text{ \ ng}/{mL}$ for BPA and BPS and ranged from 0.50 to $50\text{ \ ng}/{mL}$ for BPF. All calibration curves showed excellent linearity ($R^{2} \geq 0.9901$). Intra- and interday precisions were lower than 7.7% and 10.1% for all three bisphenols.

Specific gravity (SG) for each urine sample was measured at room temperature by a hand-held digital refractometer (Atago PAL-3; Atago), which was calibrated before each measure using deionized water.

Birth Anthropometry {#s2.3}
-------------------

Information on birth weight (in grams) and birth length (in centimeters) was retrieved from medical records. Ponderal index (in kilograms per cubic meter) was calculated as 1,000 times birth weight (in grams) divided by the cube of birth length (in meters). A low ponderal index indicates an asymmetrical intrauterine growth retardation ([@c21]). Gestational age at delivery was calculated as days between the date of delivery and the first day of the last menstrual period (LMP), which was reported by the participants and also corrected by obstetricians according to the first-trimester ultrasound measures based on clinical criteria. The information on both reported and corrected gestational ages at delivery was retrieved from medical records. For women who reported an accurate date of the LMP (i.e., the difference between the reported and corrected date of the LMP was less than 7 d), a reported gestational age was used; otherwise, an ultrasound corrected gestational age was used.

Gestational age-adjusted percentiles of birth weight, birth length, and ponderal index were calculated based on the gestational age-adjusted standard deviation scores (SD-scores) for each birth anthropometry. These SD-scores were generated based on all available data ([@c17]) using the *GAMLSS* package (version 4.3-7) in the R software (version 3.3.2; R Development Core Team). The assumption was that the distributions of these parameters depend only on gestational age. We first performed Box-Cox transformations to normalize these parameters ([@c38]). Then, we modeled each parameter as a function of gestational age in days using a cubic spline according to different distribution families (BCPEo, BCCGo, and BCTo) provided by the *GAMLSS* package. Finally, the best fitting model for each birth anthropometry with a specific distribution was selected based on the Akaike's information criteria and was then used to generate the gestational age-adjusted SD-score for each birth anthropometry.

Covariates {#s2.4}
----------

In-person interviews were conducted by trained nurses at the first prenatal care visits using standardized and structured questionnaires to collect information on maternal age, socioeconomic status (e.g., education and annual household income), perinatal lifestyle before and during pregnancy (e.g., tobacco smoking, passive smoking, and alcohol consumption), folic acid supplement use during pregnancy, and anthropometric data (maternal height and prepregnancy weight and paternal height and weight). Passive smoking was defined as being exposed to secondhand smoke during pregnancy from either family members (at home) or colleagues (at work). Maternal prepregnancy body mass index (BMI) and paternal BMI were calculated as weight (in kilograms) divided by height in meters squared. Clinical information (e.g., parity, hypertensive disorders of pregnancy, gestational diabetes mellitus, anemia, and infant sex) was retrieved from medical records, as diagnosed by experienced obstetricians at prenatal care visits as routine clinical care in the study hospital.

Statistical Analysis {#s2.5}
--------------------

Urinary concentrations (in nanograms per milliliter) of BPA, BPF, and BPS below the levels of LODs were replaced by the LODs divided by the square root of 2. For each bisphenol, we standardized its concentrations for urine dilution using the following equation: $P_{i} = P\left\lbrack {\left( {1.011–1} \right)/\left( {SG–1} \right)} \right\rbrack$, where *P* represents the unadjusted concentrations, 1.011 is the median SG of all measurements, and *SG* represents the specific gravity of individual urine samples ([@c13]). Average concentrations of each bisphenol across the three trimesters were also calculated. SG-standardized bisphenol concentrations were transformed by natural logarithm to reduce the influence of outliers. Pearson correlation coefficients of urinary concentrations of BPA, BPF, and BPS in each trimester were calculated for within-trimester comparisons.

Intraclass correlation coefficients (ICCs) and 95% confidence intervals (CIs) of urinary SG and urinary bisphenol concentrations were estimated using mixed-effects models in order to estimate their reproducibility. The ICC is the ratio of between-subject variance to total variance with a range from 0 (no reproducibility) to 1 (perfect reproducibility) ([@c41]). In addition, poor reproducibility was defined as an $\text{ICC} < 0.40$, fair-to-good reproducibility as an ICC between 0.40 and 0.75; and excellent reproducibility as an $\text{ICC} \geq 0.75$.

In order to estimate trimester-specific associations of urinary bisphenol concentrations with indicators of size at birth, we used a multiple informant model based on the repeated measures of urinary concentrations of BPA, BPF, and BPS ([@c42]). This multiple informant model treated urinary bisphenol concentrations at different time windows as informants and simultaneously estimated associations of each individual bisphenol concentrations with a given indicator of size at birth, and was conducted using linear regression with generalized estimating equations. In addition, this approach did not adjust for certain bisphenol concentrations in other time windows. Instead, it tested the null hypothesis that coefficients for certain bisphenol were equal at each visit; the *p*-value for this test, denoted as $p_{w}$, alludes to the interaction between exposure levels of bisphenols and timing of exposure ([@c42]). A $p_{w} < \, 0.05$ indicates that at least one association differed from the rest. We applied multiple informant models to estimate trimester-specific associations of urinary concentrations of BPA, BPF, and BPS in the first, second, and third trimesters with birth weight, birth length, and ponderal index. Original values of these birth anthropometric measurements were used in these multiple informant models. Regression coefficients ($\beta s$) and 95% CIs were estimated per interquartile range (IQR) increase (as continuous variables) and trimester-specific quartiles (with the lowest quartiles set as references) of urinary concentrations of each bisphenol. In order to test ordered relations across quartiles of urinary concentrations of BPA, BPF, and BPS, tests for linear trend ($p_{\text{trend}}$) were performed by modeling the median value of each quartile. Associations between average concentrations of each bisphenol across the three trimesters (per IQR increase and quartiles) and size at birth were also estimated using linear regression models.

In addition, we estimated exposure patterns for given outcome levels, using the methods of Sánchez et al. ([@c42]), to evaluate which periods of pregnancy were more likely to be critical windows of susceptibility to bisphenols. Specifically, we used separate linear mixed-effects models for each bisphenol to compare urinary concentrations according to gestational age at measurement between newborns with low- versus high-gestational age-adjusted SD-scores (in the 10th percentile vs. in the 90th percentile, respectively) for birth weight, birth length, and ponderal index.

Regression models were adjusted for gestational age at delivery (continuous, in multiple informant models), maternal age at recruitment (continuous), parity (nulliparous/multiparous), maternal prepregnancy BMI (categorized using the Chinese standard: $< 18.5/18.5–23.9/ \geq 24.0{\,{kg}/m}^{2}$), folic acid supplementation during pregnancy (no/only in the first trimester/only in the second and third trimester/during the entire pregnancy), passive smoking during pregnancy (no/yes), education ($\leq 9/9–12/ > 12\, y$), maternal and paternal height (continuous, in birth-length models), and infant sex (boys/girls). We also included urinary concentrations of BPA, BPF, and BPS in the same model in order to mutually adjust for each other.

We conducted a stratified analysis by infant sex (boys and girls) because we observed a sex-based difference in the association between prenatal exposure to BPA and birth weight risk in a previous study ([@c18]). Stratified analyses were also carried out based on maternal age at recruitment (by median age of 27 y), parity (by nulliparous and multiparous), and prepregnancy BMI \[by underweight ($< 18.5{\,{kg}/m}^{2}$), normal ($18.5–23.9{\,{kg}/m}^{2}$), and overweight and above ($\geq 24.0{\,{kg}/m}^{2}$) according to the Chinese standard\]. In addition, *p*-values for interaction ($p_{\text{interaction}}$) were estimated as the *p*-values for the interaction terms of stratified variable and urinary concentrations of each bisphenol in order to test differences in associations of each strata. As a sensitivity analysis, models were additionally adjusted for hypertensive disorders of pregnancy (no/hypertension/preeclampsia), gestational diabetes mellitus (no/yes), and anemia (no/yes) in order to test for the potential impact of pregnancy complications. Other sensitivity analyses were conducted by replicating all regression models restricted to term deliveries or women without pregnancy complications (hypertensive disorders of pregnancy, gestational diabetes mellitus, or anemia).

All statistical analyses were performed using R (version 3.3.2; R Development Core Team) or SAS (version 9.4; SAS Institute Inc.). The statistical significance level was set to 0.05 for a two-tailed test.

Results {#s3}
=======

On average, the 845 women included in the present study were $27.9 \pm 3.4\, y\text{ \ of\  \ age}$. The study participants were predominantly nulliparous (85.9%) and well educated (78.9% had at least a college-level education). Before pregnancy, 18.5% of the women were underweight ($\text{BMI} < 18.5{\,{kg}/m}^{2}$), 68.3% were within the normal weight range (BMI between 18.5 and $23.9{\,{kg}/m}^{2}$), 11.4% were overweight (BMI between 24.0 and $27.9{\,{kg}/m}^{2}$), and only 1.9% were obese ($\text{BMI} \geq 28.0{\,{kg}/m}^{2}$). A total of 283 (33.5%) women were exposed to secondhand smoking during pregnancy, and 439 (52.0%) women delivered boys ([Table 1](#t1){ref-type="table"}). The $\text{mean} \pm \text{SD}$ of birth weight was $3,319 \pm 402g$ (range: 1,700 to $4,750g$), of birth length was $50.2 \pm 1.5\,{cm}$ (range: 43.0 to $56.0\,{cm}$), and of ponderal index was $26.1 \pm 2.1{\,{kg}/m}^{3}$ (range: 19.6 to $38.2{\,{kg}/m}^{3}$). In addition, 20 (2.4%) infants were born preterm and 83 (9.8%) infants were born small for gestational age (gestational age-adjusted SD-scores for $\text{birth\  \ weight} < 10\text{th\  \ percentile}$).

###### 

Demographic and perinatal characteristics, and maternal urinary bisphenol concentrations \[medians (25th--75th percentiles)\] according to covariates of the study population from Wuhan, China (2013--2015).

Table 1 has eleven columns. The first column lists the different covariates. The second column lists n percentage or mean plus or minus S D. The adjacent columns list the values in nanograms per liter for the first, second, and third trimesters for bisphenol A, Bisphenol F, and Bisphenol S.

  Characteristics                                                      $n$ (%) or $\text{mean} \pm \text{SD}$   Bisphenol A (ng/mL)   Bisphenol F (ng/mL)   Bisphenol S (ng/mL)                                                                                         
  -------------------------------------------------------------------- ---------------------------------------- --------------------- --------------------- --------------------- ---------------- ---------------- ---------------- ---------------- ----------------- ----------------
  All participants                                                     845 (100)                                1.3 (0.1--3.4)        1.5 (0.2--3.8)        1.5 (0.3--4.4)        0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--1.0)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
  Maternal age at recruitment (y)                                                                                                                                                                                                                                       
   $< 25$                                                              105 (12.4)                               1.1 (0.03--4.3)       1.4 (0.03--4.4)       1.6 (0.03--6.8)       0.5 (0.3--1.0)   0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.3 (0.1--0.8)   0.4 (0.2--0.9)    0.4 (0.2--1.4)
   25--30                                                              517 (61.2)                               1.2 (0.03--3.2)       1.4 (0.03--3.6)       1.5 (0.3--4.1)        0.6 (0.3--1.4)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--0.9)   0.4 (0.1--1.1)    0.4 (0.2--1.1)
   30--35                                                              182 (21.5)                               1.6 (0.3--3.9)        1.7 (0.5--3.7)        1.4 (0.3--4.8)        0.6 (0.3--1.4)   0.7 (0.3--1.3)   0.7 (0.3--1.5)   0.4 (0.1--1.0)   0.4 (0.2--1.4)    0.5 (0.2--1.2)
   $\geq 35$                                                           41 (4.9)                                 1.0 (0.2--3.6)        1.7 (0.6--4.6)        1.8 (0.6--3.4)        0.5 (0.4--1.2)   0.8 (0.4--1.3)   0.6 (0.5--1.2)   0.2 (0.1--1.6)   0.5 (0.2--1.3)    0.5 (0.2--1.5)
  Maternal height (cm)                                                 $161 \pm 4$                              ---                   ---                   ---                   ---              ---              ---              ---              ---               ---
  Maternal BMI before pregnancy BMI (${{kg}/m}^{2}$)                                                                                                                                                                                                                    
   $< 18.5$                                                            156 (18.5)                               1.1 (0.03--2.6)       1.1 (0.03--2.6)       1.8 (0.4--4.0)        0.6 (0.2--1.0)   0.7 (0.3--1.3)   0.8 (0.4--1.5)   0.2 (0.1--0.8)   0.3 (0.1--0.9)    0.5 (0.2--1.3)
   18.5--23.9                                                          577 (68.3)                               1.4 (0.1--3.8)        1.5 (0.3--4.2)        1.5 (0.3--4.5)        0.6 (0.3--1.4)   0.7 (0.4--1.3)   0.7 (0.4--1.5)   0.3 (0.1--0.9)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   24.0--27.9                                                          96 (11.4)                                1.1 (0.1--3.5)        1.4 (0.03--3.1)       1.3 (0.1--4.6)        0.6 (0.3--1.9)   0.8 (0.4--2.0)   0.6 (0.3--1.3)   0.3 (0.2--1.6)   0.6 (0.2--1.4)    0.4 (0.2--1.0)
   $\geq 28.0$                                                         16 (1.9)                                 1.2 (0.03--2.4)       1.9 (0.5--4.7)        1.7 (0.1--2.7)        0.7 (0.2--1.2)   0.6 (0.2--1.3)   0.6 (0.2--1.7)   0.4 (0.1--0.9)   0.3 (0.1--0.5)    0.2 (0.1--0.9)
  Parity                                                                                                                                                                                                                                                                
   Nulliparous                                                         726 (85.9)                               1.2 (0.1--3.4)        1.4 (0.1--3.8)        1.6 (0.3--4.5)        0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--0.9)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   Multiparous                                                         119 (14.1)                               1.5 (0.1--3.6)        1.6 (0.4--3.8)        1.2 (0.3--3.6)        0.6 (0.3--1.7)   0.6 (0.3--1.3)   0.7 (0.3--1.3)   0.3 (0.1--1.4)   0.4 (0.2--1.2)    0.3 (0.1--0.8)
  Hypertensive disorders in pregnancy                                                                                                                                                                                                                                   
   No                                                                  823 (97.4)                               1.3 (0.1--3.5)        1.5 (0.1--3.8)        1.5 (0.3--4.4)        0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--1.0)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   Hypertension                                                        18 (2.1)                                 0.7 (0.03--2.0)       1.4 (0.3--4.6)        1.5 (0.1--7.8)        0.5 (0.2--1.0)   1.0 (0.2--2.3)   0.5 (0.2--0.7)   0.3 (0.1--0.8)   0.7 (0.4--1.9)    0.5 (0.2--1.2)
   Preeclampsia                                                        4 (0.5)                                  0.8 (0.2--2.3)        2.0 (1.0--4.0)        2.4 (1.5--8.9)        0.6 (0.4--3.0)   0.5 (0.2--11)    0.8 (0.3--3.3)   0.3 (0.2--0.4)   0.3 (0.3--0.7)    0.3 (0.1--1.7)
  Gestational diabetes mellitus                                                                                                                                                                                                                                         
   No                                                                  769 (91.0)                               1.2 (0.05--3.4)       1.4 (0.1--3.8)        1.5 (0.3--4.5)        0.6 (0.3--1.3)   0.7 (0.3--1.3)   0.7 (0.4--1.4)   0.3 (0.1--0.9)   0.4 (0.1--1.1)    0.4 (0.2--1.2)
   Yes                                                                 76 (9.0)                                 1.4 (0.3--3.7)        1.5 (0.3--4.1)        1.1 (0.3--3.2)        0.6 (0.4--1.9)   0.8 (0.4--1.8)   0.8 (0.4--2.2)   0.3 (0.1--1.2)   0.5 (0.1--1.3)    0.5 (0.2--1.5)
  Maternal anemia during pregnancy                                                                                                                                                                                                                                      
   No                                                                  813 (96.2)                               1.3 (0.1--3.4)        1.4 (0.2--3.8)        1.5 (0.3--4.5)        0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--1.0)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   Yes                                                                 32 (3.8)                                 1.3 (0.2--3.5)        1.9 (0.03--4.2)       1.4 (0.6--3.2)        0.4 (0.3--0.7)   0.7 (0.3--1.4)   0.5 (0.3--1.6)   0.1 (0.1--0.3)   0.2 (0.05--0.5)   0.3 (0.1--0.7)
  Maternal pregnancy complications[^*a*^](#TF2){ref-type="table-fn"}                                                                                                                                                                                                    
   None                                                                724 (85.7)                               1.3 (0.1--3.4)        1.4 (0.1--3.8)        1.5 (0.3--4.5)        0.6 (0.3--1.3)   0.7 (0.4--1.3)   0.7 (0.4--1.4)   0.3 (0.1--1.0)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   At least one                                                        121 (14.3)                               1.3 (0.2--3.4)        1.5 (0.3--3.8)        1.3 (0.4--3.4)        0.6 (0.3--1.5)   0.8 (0.3--1.9)   0.6 (0.3--1.8)   0.2 (0.1--0.9)   0.5 (0.1--1.1)    0.4 (0.2--1.1)
  Maternal passive smoking during pregnancy                                                                                                                                                                                                                             
   No                                                                  562 (66.5)                               1.2 (0.03--3.4)       1.4 (0.2--3.8)        1.5 (0.3--4.2)        0.6 (0.3--1.4)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--1.0)   0.4 (0.1--1.3)    0.4 (0.2--1.2)
   Yes                                                                 283 (33.5)                               1.3 (0.3--3.5)        1.5 (0.2--3.8)        1.5 (0.3--4.8)        0.6 (0.3--1.3)   0.6 (0.3--1.3)   0.7 (0.3--1.5)   0.3 (0.1--0.9)   0.4 (0.1--0.9)    0.4 (0.2--1.2)
  Maternal education (y)                                                                                                                                                                                                                                                
   $\leq 9$                                                            50 (5.9)                                 1.2 (0.03--2.8)       1.4 (0.3--3.8)        1.2 (0.2--3.9)        0.7 (0.4--1.3)   0.8 (0.4--1.3)   0.7 (0.4--1.5)   0.3 (0.2--1.2)   0.5 (0.3--1.7)    0.5 (0.2--2.3)
   9--12                                                               128 (15.1)                               1.3 (0.4--3.8)        1.3 (0.2--3.8)        1.6 (0.4--4.1)        0.6 (0.3--1.2)   0.7 (0.3--1.2)   0.7 (0.4--1.5)   0.3 (0.1--0.8)   0.3 (0.1--1.0)    0.4 (0.2--1.0)
   $> 12$                                                              667 (78.9)                               1.2 (0.03--3.4)       1.5 (0.1--3.8)        1.5 (0.3--4.5)        0.6 (0.3--1.4)   0.7 (0.4--1.4)   0.7 (0.3--1.5)   0.3 (0.1--1.0)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
  Maternal folic acid supplementation during pregnancy                                                                                                                                                                                                                  
   No                                                                  196 (23.2)                               1.2 (0.1--3.3)        1.4 (0.2--4.1)        1.7 (0.4--6.2)        0.6 (0.3--1.1)   0.8 (0.4--1.4)   0.7 (0.4--1.7)   0.3 (0.1--0.9)   0.4 (0.2--1.0)    0.5 (0.2--1.3)
   1st trimester only                                                  295 (34.9)                               1.3 (0.1--3.7)        1.5 (0.2--3.9)        1.6 (0.3--4.2)        0.6 (0.3--1.5)   0.6 (0.3--1.3)   0.7 (0.3--1.3)   0.3 (0.1--1.1)   0.4 (0.1--1.3)    0.4 (0.2--1.1)
   2nd and 3rd trimesters                                              139 (16.4)                               1.0 (0.1--2.9)        1.5 (0.03--3.8)       1.2 (0.03--3.8)       0.6 (0.3--1.2)   0.6 (0.3--1.4)   0.6 (0.4--1.5)   0.3 (0.1--0.8)   0.3 (0.1--1.2)    0.4 (0.2--1.3)
   Entire pregnancy                                                    215 (25.4)                               1.4 (0.03--3.5)       1.3 (0.03--3.2)       1.4 (0.2--3.5)        0.6 (0.3--1.4)   0.7 (0.4--1.3)   0.8 (0.4--1.6)   0.3 (0.1--1.1)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
  Paternal height (cm)                                                 $174 \pm 5$                              ---                   ---                   ---                   ---              ---              ---              ---              ---               ---
  Infant sex                                                                                                                                                                                                                                                            
   Male                                                                439 (52.0)                               1.2 (0.05--3.4)       1.4 (0.1--3.9)        1.5 (0.2--4.2)        0.6 (0.3--1.4)   0.7 (0.4--1.3)   0.7 (0.4--1.3)   0.3 (0.1--1.0)   0.4 (0.2--1.3)    0.5 (0.2--1.2)
   Female                                                              406 (48.0)                               1.3 (0.1--3.5)        1.5 (0.2--3.6)        1.5 (0.3--4.5)        0.6 (0.3--1.3)   0.7 (0.3--1.4)   0.7 (0.3--1.6)   0.3 (0.1--0.8)   0.4 (0.1--1.1)    0.4 (0.1--1.2)
  Preterm delivery                                                                                                                                                                                                                                                      
   No                                                                  825 (97.6)                               1.2 (0.1--3.4)        1.4 (0.1--3.8)        1.5 (0.3--4.2)        0.6 (0.3--1.3)   0.7 (0.4--1.4)   0.7 (0.4--1.5)   0.3 (0.1--0.9)   0.4 (0.1--1.2)    0.4 (0.2--1.2)
   Yes                                                                 20 (2.4)                                 3.0 (1.0--5.6)        2.9 (1.8--6.8)        3.0 (0.9--6.9)        0.6 (0.3--1.4)   0.5 (0.3--1.0)   0.4 (0.2--0.7)   0.5 (0.1--1.4)   0.4 (0.2--1.3)    0.3 (0.1--0.8)

Note: Data are complete for all variables shown. ---, Not applicable; BMI, body mass index; SD, standard deviation.

Pregnancy complications include hypertensive disorders in pregnancy, gestational diabetes mellitus, and anemia during pregnancy.

The detection rate of BPA in all urine samples was 76.9% (1,950 samples), which was lower than that for BPF (98.3%, 2,492 samples) or BPS (86.8%, 2,200 samples). The median of BPA was 1.40 (IQR: 0.19--3.85) ng/mL in all urine samples, which was higher than for BPF ($\text{median} = 0.65\text{ \ ng}/{mL}$; IQR: $0.34–1.39\text{ \ ng}/{mL}$) or BPS ($\text{median} = 0.38\text{ \ ng}/{mL}$; IQR: $0.13–1.11\text{ \ ng}/{mL}$). Urinary concentrations of BPA, BPF, and BPS increased slightly during pregnancy (see Table S1) and were similar across different strata of covariates and some demographic and perinatal characteristics ([Table 1](#t1){ref-type="table"}). Urinary bisphenol concentrations of women included in the present study were compared with those of other populations from different countries in North America, Europe, and Asia ([Table 2](#t2){ref-type="table"}). Urinary BPA concentrations of the study population were generally lower than that of other populations, whereas urinary concentrations of BPF and BPS were similar or higher than those of other populations.

###### 

Urinary concentration comparisons.

Table 2 has nine columns. Study, location, sample years, number, and samples are located in the first, second, third, fourth, and fifth columns, respectively. The adjacent columns list value, bisphenol A details, Bisphenol F details, and Bisphenol S details for urinary bisphenol concentrations (nanograms per milliliter).

  Study                                             Location                                   Sample years                                       $n$                                     Samples                                         Urinary bisphenol concentrations (ng/mL)                                                       
  ------------------------------------------------- ------------------------------------------ -------------------------------------------------- --------------------------------------- ----------------------------------------------- -------------------------------------------------- --------------------- --------------------- -------------------------
  Preconception or pregnant women                                                                                                                                                                                                                                                                                                        
   Present study                                    Wuhan, China                               2013--2015                                         845                                     T1 (13.0 weeks)                                 Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.3 (0.1--3.4)        0.6 (0.3--1.3)        0.3 (0.1--1.0)
  GM (95% CI)                                       0.8 (0.7, 0.9)                             0.6 (0.6, 0.7)                                     0.3 (0.3, 0.4)                                                                                                                                                                         
  845                                               T2 (23.6 weeks)                            Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.5 (0.2--3.8)                          0.7 (0.4--1.4)                                  0.4 (0.1--1.2)                                                                                 
  GM (95% CI)                                       0.9 (0.7, 1.0)                             0.7 (0.6, 0.8)                                     0.4 (0.4, 0.4)                                                                                                                                                                         
  845                                               T3 (36.0 weeks)                            Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.5 (0.3--4.4)                          0.7 (0.4--1.5)                                  0.4 (0.2--1.2)                                                                                 
  GM (95% CI)                                       1.0 (0.8, 1.1)                             0.7 (0.7, 0.8)                                     0.5 (0.4, 0.5)                                                                                                                                                                         
  2,535                                             All samples                                Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.4 (0.2--3.9)                          0.7 (0.3--1.4)                                  0.4 (0.1--1.1)                                                                                 
  GM (95% CI)                                       0.9 (0.8, 0.9)                             0.7 (0.7, 0.7)                                     0.4 (0.4, 0.4)                                                                                                                                                                         
  ICC (95% CI)[^*b*^](#TF5){ref-type="table-fn"}    0.34 (0.30, 0.39)                          0.57 (0.54, 0.61)                                  0.45 (0.41, 0.49)                                                                                                                                                                      
   [@c36] (CHAMACOS)                                USA                                        1999--2000                                         407                                     T1 (14 weeks)                                   GM (GSD)                                           0.9 (2.8)             ---                   ---
  GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}        1.2 (2.4)                                  ---                                                ---                                                                                                                                                                                    
  459                                               T2 (26 weeks)                              GM (GSD)                                           1.0 (2.6)                               ---                                             ---                                                                                            
  GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}        1.2 (2.2)                                  ---                                                ---                                                                                                                                                                                    
  ICC                                               0.22                                       ---                                                ---                                                                                                                                                                                    
  ICC[^*b*^](#TF5){ref-type="table-fn"}             0.16                                       ---                                                ---                                                                                                                                                                                    
   [@c16] (CCCEH)                                   USA                                        1999--2006                                         375                                     T3 (34.7 weeks)                                 GM (95% CI)                                        1.8 (1.7, 2.0)        ---                   ---
   [@c34]                                           French[^*c*^](#TF6){ref-type="table-fn"}   2002--2006                                         191                                     6--30 weeks[^*c*^](#TF6){ref-type="table-fn"}   Med (5--95th)                                      3.1 (0.8--10)         ---                   ---
   [@c19] (Generation R)                            the Netherlands                            2002--2006                                         80                                      $< 18\text{ \ weeks}$                           Med (25--75th)                                     1.1 (0.6--3.3)        ---                   ---
  80                                                18--25 weeks                               Med (25--75th)                                     1.5 (0.6--3.2)                          ---                                             ---                                                                                            
  80                                                $> 25\text{ \ weeks}$                      Med (25--75th)                                     1.6 (0.8--2.6)                          ---                                             ---                                                                                            
  ICC (95% CI)                                      0.32 (0.18--0.46)                          ---                                                ---                                                                                                                                                                                    
   [@c9] (EARTH)                                    USA                                        2004--2009                                         137                                     Preconception                                   Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.5 (1.1--2.1)        ---                   ---
  ICC[^*b*^](#TF5){ref-type="table-fn"}             0.27                                       ---                                                ---                                                                                                                                                                                    
  137                                               During pregnancy                           Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   1.5 (1.1--2.3)                          ---                                             ---                                                                                            
  ICC[^*b*^](#TF5){ref-type="table-fn"}             0.37                                       ---                                                ---                                                                                                                                                                                    
   [@c11] (INMA--Sabadell)                          Spain                                      2004--2006                                         470                                     T1 and T3                                       GM (95% CI)                                        2.3 (2.1, 2.4)        ---                   ---
  ICC (95% CI)                                      0.15 (0.06, 0.24)                          ---                                                ---                                                                                                                                                                                    
   [@c47] (INMA--Sabadell)                          Spain                                      2004--2006                                         402                                     T1 (12 weeks)                                   Med (25--75th)                                     2.0 (1.2--3.6)        ---                   ---
  T3 (32 weeks)                                     Med (25--75th)                             1.8 (1.0--3.2)                                     ---                                     ---                                                                                                                                            
  Average                                           Med (25--75th)                             2.2 (1.4--3.6)                                     ---                                     ---                                                                                                                                            
   [@c8] (MIREC)                                    Canada                                     2005--2009                                         812                                     T1 (12 weeks)                                   Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   0.8 (0.1--1.5)        ---                   ---
   [@c44]                                           USA                                        2005--2009                                         213                                     Preconception                                   GM (95% CI)                                        0.4 (0.3, 0.5)        ---                   ---
  ICC (95% CI)                                      0.38 (0.31--0.45)                          ---                                                ---                                                                                                                                                                                    
   [@c10]                                           USA                                        2006--2008                                         351                                     Visit 1 (9.7 weeks)                             GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}         1.3 (2.3)             ---                   ---
  304                                               Visit 2 (17.9 weeks)                       GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}         1.3 (2.1)                               ---                                             ---                                                                                            
  301                                               Visit 3 (26.0 weeks)                       GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}         1.4 (2.3)                               ---                                             ---                                                                                            
  314                                               Visit 4 (35.1 weeks)                       GM (GSD)[^*a*^](#TF4){ref-type="table-fn"}         1.3 (2.2)                               ---                                             ---                                                                                            
  ICC (95% CI)[^*b*^](#TF5){ref-type="table-fn"}    0.19 (0.14, 0.26)                          ---                                                ---                                                                                                                                                                                    
   [@c15] (LIFECODES)                               USA                                        2006--2008                                         476                                     T1, T2, and T3                                  Med (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   ---                   ---                   $< 0.4$ ($< 0.4 - 0.6$)
   [@c30] (Rhea)                                    Greece                                     2007--2008                                         239                                     T1 (10--13 weeks)                               GM (95% CI)                                        1.2 (1.1, 1.4)        ---                   ---
   [@c28] (PROTECT)                                 Puerto Rico                                2010--2012                                         105                                     During pregnancy                                GM (95% CI)[^*a*^](#TF4){ref-type="table-fn"}      2.6 (2.3, 2.9)        ---                   ---
  ICC (95% CI)[^*b*^](#TF5){ref-type="table-fn"}    0.24 (0.13, 0.40)                          ---                                                ---                                                                                                                                                                                    
   [@c18] (HBC)                                     Wuhan, China                               2012--2014                                         339[^*d*^](#TF7){ref-type="table-fn"}   Before delivery                                 GM (95% CI)                                        2.1 (1.7, 2.5)        ---                   ---
   [@c48] (HBC)                                     Wuhan, China                               2012--2014                                         985                                     Before delivery                                 GM (25--75th)                                      ---                   ---                   0.2 (0.1--0.4)
  GM (25--75th)[^*a*^](#TF4){ref-type="table-fn"}   ---                                        ---                                                0.2 (0.1--0.4)                                                                                                                                                                         
  General population                                                                                                                                                                                                                                                                                                                     
   [@c51]                                           Tianjin, China                             2010                                               50                                      Men and women                                   Med (range)                                        1.6 ($< 0.1 - 8.7$)   ---                   ---
  23                                                Women                                      Med (range)                                        1.7 ($< 0.1 - 8.7$)                     ---                                             ---                                                                                            
   [@c27] (NHANES)                                  USA                                        2013--2014                                         1,521                                   Men and women                                   Med (25--75th)                                     1.3 (0.6--2.5)        0.3 (0.1--1.1)        0.4 (0.1--0.9)
   [@c50] (NHANES)                                  USA                                        2014                                               42                                      Men and women                                   GM (95% CI)                                        0.4 ($< 0.1$, 5.2)    0.4 (0.3, 0.6)        0.3 ($< 0.1$, 3.1)
   [@c52]                                           Longtang Town, China                       2014                                               116                                     Adults in e-waste area                          Med (range)                                        3.0 (0.2--27.6)       0.4 ($< 0.1 - 8.7$)   0.4 ($< 0.1 - 1.4$)
   [@c52]                                           Qingyuan City, China                       2014                                               22                                      Adults in rural area                            Med (range)                                        0.6 ($< 0.1 - 4.1$)   0.1 ($< 0.1 - 0.9$)   0.4 (0.2--1.1)
  20                                                Adults in urban area                       Med (range)                                        1.4 ($< 0.1 - 4.1$)                     0.5 (0.1--3.0)                                  0.8 (0.1--1.6)                                                                                 

Note: ---, Not applicable; CCCEH, Columbia Center for Children's Environmental Health; CHAMACOS, Center for the Health Assessment of Mothers and Children of Salinas; CI, confidence interval; EARTH, Environment and Reproductive Health Study; GM, geometric mean; GSD, geometric standard deviation; HBC, Healthy Baby Cohort; ICC, intraclass coefficient; INMA-Sabadell, INfancia y Medio Ambiente study in Sabadell, Spain; LIFECODES, the LifeCodes Cohort in Boston, Massachusetts; Med, median; MIREC, Maternal-Infant Research on Environmental Chemicals; NHANES, National Health and Nutrition Examination Survey; PROTECT, Puerto Rico Testsite for Exploring Contamination Threats; Rhea, the mother--child cohort study in Crete; SG, specific gravity; T, trimester.

SG-adjusted urinary bisphenol concentration (ng/mL).

ICCs and/or 95% CIs for SG-adjusted urinary bisphenol A concentrations.

The study population was from two French birth cohorts: EDEN (Etude des Déterminants pré et post natals du développement et de la santé de l'Enfant) and PELAGIE (Perturbateurs endocriniens: Étude Longitudinale sur les Anomalies de la Grossesse, l'Infertilité et l'Enfance) mother--child cohorts. Urinary samples were collected at 6--19 weeks (PELAGIE) and 24--30 weeks (EDEN).

Urinary bisphenol A concentrations of controls for the nested case--control study.

Urinary concentrations of BPA, BPF, and BPS were weakly correlated with each other, with Pearson correlation coefficients in each trimester between 0.10 and 0.31 (see Table S2). The ICC of urinary BPA concentrations throughout the whole pregnancy was 0.34 (95% CI: 0.30, 0.39), indicating a poor reproducibility during pregnancy. But both urinary concentrations of BPF \[$\text{ICC} = 0.57$ (95% CI: 0.54, 0.61)\] and BPS \[$\text{ICC} = 0.45$ (95% CI: 0.41, 0.49)\] had fair reproducibility during pregnancy. Similar ICCs of urinary bisphenol concentrations between each individual trimesters were also observed (see Table S3). Moreover, urinary SG of the study population had a low reliability \[$\text{ICC} = 0.18$ (95% CI: 0.14, 0.23)\] throughout the whole pregnancy, as well as between different trimesters.

After adjustment for potential confounders, urinary BPA concentrations in different trimesters were inversely, but not significantly, associated with birth weight and ponderal index, and urinary concentrations of BPF and BPS were inversely associated with birth weight, birth length, or ponderal index with some statistically significant findings ([Figure 1](#f1){ref-type="fig"}). Each IQR increase in urinary BPF concentration in the first trimester was associated with reduced birth weight \[$\beta\, =$ $- 27$ (95% CI: $- 55$, $0\, g$)\], and a significant reduction in ponderal index \[$\beta\, =$$- 0.17$ (95% CI: $- 0.32$, $- 0.02{\,{kg}/m}^{3}$)\] was associated with each IQR increase in urinary BPF concentrations in the third trimester. The associations were not significantly different across trimesters ($p_{w} > 0.1$). An IQR increase in urinary BPS concentrations in the first trimester was significantly associated with reduced birth weight \[$\beta\, =$$- 38$ (95% CI: $- 65$, $- 11\, g$)\] and ponderal index \[$\beta\, =$$- 0.18$ (95% CI: $- 0.34$, $- 0.02{\,{kg}/m}^{3}$)\], and the second-trimester concentrations of urinary BPS were significantly associated with reduced birth weight \[$\beta\, =$$- 43$ (95% CI: $- 71$, $- 15\, g$)\] and birth length \[$\beta\, =$ $- 0.12$ (95% CI: $- 0.23$, $- 0.02\,{cm}$)\]. Notably, associations between urinary BPS concentrations and birth weight were significantly different across trimesters ($p_{w} = 0.01$) but not for birth length and ponderal index ($p_{w} > 0.1$). Associations for average concentrations of each bisphenol across the three trimesters were generally in the same direction as trimester-specific associations but were mostly nonsignificant. Mean birth weight, birth length, and ponderal index decreased across increasing quartiles of urinary concentrations of BPF and BPS in different trimesters, as did average concentrations ([Figure 2](#f2){ref-type="fig"}; see also Table S4). In addition, after adjusting for other bisphenols, similar inverse associations of urinary concentrations of BPF and BPS with size at birth were observed, and these associations remained significant. Moreover, when additionally adjusting for pregnancy complications, the observed associations did not change when compared with those from the primary analysis (see Table S5).

![Associations between urinary bisphenol concentrations (per interquartile range increase) and size at birth. Regression coefficients ($\beta s$) and 95% confidence intervals (CIs) for trimester-specific associations of urinary concentrations of bisphenol A (BPA), bisphenol F (BPF), and bisphenol S (BPS) (per interquartile range) with original values of birth weight (in grams), birth length (in centimeters), and ponderal index (in kilograms per cubic meter) were estimated using multiple informant models. Associations between average concentrations of each bisphenol across the three trimesters were estimated using linear regression models. The single bisphenol models were adjusted for gestational age at delivery, maternal age at recruitment, parity, prepregnancy body mass index, passive smoking during pregnancy, education, folic acid supplementation, infant sex, and maternal and paternal height (only in birth length models). The mutual adjustment models were adjusted for variables in the single bisphenol models and mutually adjusted for urinary concentrations of BPA, BPF, and BPS. Trimester-specific interquartile ranges for BPA, BPF, and BPS are provided in Table S1. $p_{w} < 0.05$ indicates that associations were statistically different across trimesters.](ehp-127-107001-g001){#f1}

![Associations between quartiles of urinary bisphenol concentrations and size at birth. Regression coefficients ($\beta s$) and 95% confidence intervals (CIs) for associations of trimester-specific quartiles of urinary concentrations of bisphenol A, bisphenol F, and bisphenol S with original values of birth weight (in grams), birth length (in centimeters) and ponderal index (in kilograms per cubic meter) were estimated using multiple informant models. Associations between quartiles of average concentrations of each bisphenol across the three trimesters were estimated using linear regression models. All models were adjusted for gestational age at delivery, maternal age at recruitment, parity, prepregnancy body mass index, passive smoking during pregnancy, education, folic acid supplementation, and infant sex. Birth length models were additionally adjusted for maternal and paternal height. Numeric data are available in Table S4.](ehp-127-107001-g002){#f2}

Urinary bisphenol concentration patterns for women who delivered newborns in the 10th percentiles of birth weight, birth length, or ponderal index compared with those in the 90th percentiles are shown in [Figure 3](#f3){ref-type="fig"}. For newborns in the 10th percentile of birth weight and birth length, maternal exposure levels of BPF and BPS were relatively higher than for newborns in the 90th percentile across the period of 10--36 weeks of gestation. In addition, mothers of newborns with a ponderal index in the 10th percentile had higher BPF concentrations across pregnancy but declining BPS concentrations across pregnancy. In addition, similar trends were observed in sensitivity analyses restricted to term deliveries (see Figure S1) and in sensitivity analyses restricted to women without pregnancy complications (see Figure S2).

![Relative exposure of bisphenols comparing newborns in the 10th percentile of birth weight, birth length, or ponderal index to those in the 90th percentile. Solid lines represent relative exposures of bisphenol A, bisphenol F, or bisphenol S in the 10th percentile of birth weight, birth length, or ponderal index to those in the 90th percentiles. Dotted lines represent pointwise 95% confidence intervals. All models were adjusted for maternal age at recruitment, parity, prepregnancy body mass index, passive smoking during pregnancy, hypertensive disorders of pregnancy, gestational diabetes mellitus, education, and infant sex. Models for birth length were additionally adjusted for maternal and paternal height.](ehp-127-107001-g003){#f3}

In stratified analyses, we did not observe notable effect modifications by infant sex, parity, maternal age at recruitment, or maternal prepregnancy BMI ($p_{\text{interaction}} > 0.05$; see Table S6). The inverse associations between urinary bisphenol concentrations and birth weight were relatively more pronounced for boys, although the sex-based differences were not statistically significant ($p_{\text{interaction}} > 0.1$). Urinary BPA concentrations were inversely associated with ponderal index in nulliparous women and younger women ($\leq 27\, y\text{ \ of\  \ age}$), but were positively associated with ponderal index among multiparous women and older women ($> 27\, y\text{ \ of\  \ age}$); the parity-based and age-based differences were marginally significant ($p_{\text{interaction}} < 0.1$). Moreover, results of sensitivity analyses restricted to term deliveries (see Table S7) or to women without pregnancy complications (see Table S8) did not change appreciably when compared with those of the primary analysis.

Discussion {#s4}
==========

In the present study, we examined and compared the trimester-specific associations of prenatal exposure to BPA, BPF, and BPS with size at birth in 845 women from a longitudinal prenatal cohort in Wuhan, China. We did not observe associations between urinary BPA concentrations during pregnancy and birth anthropometry. Instead, we observed that urinary concentrations of BPF and BPS in some trimesters were significantly associated with reduced birth weight, birth length, or ponderal index and that the associations were generally unchanged after additionally adjusting for other bisphenols. Moreover, newborns with smaller size at birth were born to women with relatively higher urinary concentrations of BPF and BPS during the course of pregnancy.

Urinary BPA concentrations in general populations have been decreasing since 2000 and 2014, whereas urinary concentrations of BPF and BPS have been increasing ([@c50]). In our participants, recruited between 2013 and 2015, the medians of urinary BPA concentrations were lower than in pregnant women from our previous study ([@c18]) or in a general population from Tianjin, China ([@c51]). Urinary BPA concentrations of our participants were also relatively lower than preconception or pregnant women from different regions in the United States ([@c9]; [@c10]; [@c16]; [@c28]; [@c36]), Spain ([@c11]; [@c47]), Greece ([@c30]), France ([@c34]), and the Netherlands ([@c19]). It is noteworthy that most of those studies collected the urine samples between 1999 and 2012. Urinary BPA concentrations of women from a 10-city Canadian birth cohort, carried out between 2008 and 2011, were similar to that of our participants ([@c8]). To our knowledge, only a study of Michigan and Texas women who were trying to conceive, conducted between 2005 and 2009, reported a urinary BPA concentration \[$\text{geometric\  \ mean\  } =$ 0.38 (95% CI: 0.31, 0.45) ng/mL\] lower than the present study ([@c44]). Furthermore, urinary concentrations of BPF and BPS for women in the present study were similar to or higher than those in general populations sampled between 2009 and 2015 from urban China ([@c52]) and the United States ([@c27]; [@c50]). No studies have reported urinary BPF concentrations in pregnant women. Only two recent studies reported urinary BPS concentrations during pregnancy that were lower than in the women in the present study. One of those two studies was carried out in the United States between 2006 and 2008 ([@c15]) and the other was one of our previous studies conducted between 2012 and 2014 ([@c48]). Based on the comparisons, we could conclude a downward trend for urinary BPA concentrations and upward trends for urinary concentrations of BPF and BPS across time at population levels. A potential explanation could be the widespread use of BPA-free products in recent years. In addition, our participants had relatively higher education levels, and they might intentionally avoid using products containing BPA before and during pregnancy.

Urinary BPA concentrations of the study population indicated poor reproducibility during pregnancy, which was consistent with previous studies ([@c7], [@c9]; [@c10]; [@c11]; [@c19]). The poor reproducibility during pregnancy might be a result of the short half-life ($\sim 6\, h$) of BPA excreted from the human body ([@c12]). Similarly, the half-life of BPS excreted from the human body is $< 7\, h$ ([@c31]). We are unaware of any studies estimating the half-life of BPF. Moreover, we are not aware of any studies reporting the reproducibility of urinary concentrations of BPF and BPS during pregnancy. In the present study, we observed fair reproducibility for urinary concentrations of BPF and BPS, suggesting that BPF and BPS could have been used in additional products rather than only being used as BPA replacements. Future studies could investigate the exposure sources of BPF and BPS for humans, as well as other BPA substitutes.

Prenatal exposure to BPA in ewes at environmentally relevant doses was associated with reduced body weight in their offspring ([@c43]). However, the impact of prenatal exposure to BPA on size at birth is not clearly understood because of the inconsistent findings from current epidemiological studies ([@c33]). In a nested case--control study of low birth weight ($\text{birth\  \ weight} < 2,500\, g$; 113 cases and 339 matched controls), urinary BPA concentrations in the third trimester were associated with increased risk of low birth weight ([@c18]). A prospective cohort study from the Netherlands reported that higher urinary BPA concentrations during pregnancy were associated with reduced fetal weight, measured by ultrasound, and birth weight ([@c45]). Another nested case--control study, from the United States, related urinary BPA concentrations during pregnancy with increased risk of preterm delivery ([@c10]). On the contrary, a study from South Korea reported a positive association of urinary BPA concentrations in the third trimester with birth weight ([@c22]). A French cohort also revealed positive associations of BPA exposure during pregnancy and head circumference at birth ([@c34]). However, the present study and studies from the United States ([@c14]; [@c44]) and Spain ([@c11]) did not support associations of BPA exposures before and during pregnancy with fetal growth. Therefore, more studies are needed to investigate the effect of exposure to BPA during pregnancy on fetal growth in humans.

To our knowledge, no epidemiological studies have estimated the relationship between BPF exposure during pregnancy and fetal growth, but there were two studies for BPS. One study, from our research team, reported that urinary BPS concentration in the third trimester was significantly associated with increased pregnancy duration, but BPS was not significantly associated with reduced birth weight ([@c48]); urine samples in the first and second trimesters were not available. The other study was conducted in the United States and suggested inverse associations between urinary BPS concentrations during pregnancy, at up to three time points, and birth weight in boys ([@c15]). In the present study, the observed inverse associations of urinary concentrations of BPF and BPS with birth weight were also relatively more pronounced in boys, but the sex-based difference was not significant. Future studies with larger sample sizes are needed to investigate whether there are sex-specific effects of BPF and BPS on size at birth.

Fetuses are more sensitive to environmental exposures than adults ([@c6]). Identifying critical windows of susceptibility to environmental pollutant exposures during pregnancy is particularly crucial for researching infants' and children's health ([@c42]). Prenatal exposure to bisphenols during critical windows of susceptibility could have larger effects, compared with exposures during other time periods, on fetal growth ([@c3]; [@c42]). In the present study, using multiple informant models, we observed significantly different inverse associations between urinary BPS concentrations and birth weight across trimesters, suggesting relatively stronger associations for the exposure in first and second trimesters. But the multiple informant model is not robust to identify accurate windows of susceptibility (e.g., exposure at which exact weeks of gestational has stronger associations), and this approach is not able to account for variability in exposures within a given time window. We thus estimated exposure patterns during pregnancy by comparing newborns with low- versus high-gestational age-adjusted SD-scores. The results indicate that the exposure levels of BPF and BPS for newborns with restricted size at birth were relatively higher throughout the whole pregnancy, especially between 10 and 36 weeks of gestation. Therefore, the whole pregnancy appears to be the critical window of susceptibility to BPF and BPS for fetal growth.

As manufacturers are switching to using BPF or BPS in their products instead of BPA ([@c5]; [@c39]), the amount of both bisphenols in everyday products could continue to increase. As a result, humans are exposed to BPF and BPS simultaneously through different sources. Our findings suggest that prenatal exposure to higher levels of BPF and BPS might be associated with reduced size at birth, and significant inverse associations were relatively more pronounced for birth weight and ponderal index. Ponderal index has been used as an indicator of asymmetrical intrauterine growth restriction ([@c21]). The observed significant associations for ponderal index in our data were more likely to be driven by the associations for birth weight. Furthermore, exposure to bisphenols alters steroidogenesis in experimental animals and humans, and might affect fetal growth through multiple hormone-mediated mechanisms when exposed prenatally ([@c32]; [@c39]; [@c46]). But the exact mechanisms underlying the inverse association between prenatal exposure to bisphenols and fetal growth remain unclear, especially for substitutes of BPA. Therefore, future studies are necessary to investigate the interaction effects of prenatal exposure to different bisphenols on fetal growth, as well as the underlying mechanisms.

One strength of the present study is the repeated measurements of urinary bisphenol concentrations. This enabled us to investigate the trimester-specific associations of bisphenol exposures with size at birth, as well as to estimate the critical windows of susceptibility to bisphenols. In addition, the present study had a large sample size of 845 women who provided urine samples in each of the first, second, and third trimesters, which provided enough power to investigate the associations between prenatal exposure to bisphenols and size at birth as well as to detect sex-specific effects. Finally, we measured urinary concentrations of BPA, BPF, and BPS using the state-of-the-art method and obtained accurate and reliable exposure assessments of these bisphenols, which also enabled us to mutually adjust for all three bisphenols.

A limitation of the present study is the potential for residual confounding from other environmental toxicants. Humans are simultaneously exposed to a large number of environmental pollutants, and many of those have been related with restricted fetal growth, including other endocrine-disrupting chemicals, persistent organic pollutants, heavy metals, and airborne pollutants ([@c54]). Future studies investigating the impact of exposure to environmental chemical mixtures during pregnancy on fetal growth would help in understanding and controlling for this kind of residual confounding. Another limitation is that we did not systemically evaluate maternal diet during pregnancy, which might affect the fetal growth and also be a source of bisphenol exposures ([@c40]). Future studies are needed to investigate the impact of maternal diet and intrauterine nutritional conditions on the association of bisphenol exposures with fetal growth.

Conclusions {#s5}
===========

In this prospective prenatal cohort study, we observed significant inverse associations of urinary concentrations of BPF and BPS in some trimesters with birth weight, birth length, or ponderal index. But such inverse associations were not significant for BPA. We did not identify clear differences in associations according to trimester of exposure for BPF and BPS, suggesting that the entire gestational period may be a window of heightened susceptibility to these BPA replacements with regard their effects on fetal growth in humans. However, the observed associations in the present study need to be replicated in other populations, and sex-specific associations also need to be examined.
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